Two years in, the team at NousCom bags $49M to fund first human studies of neoantigen drugs
As NousCom CEO Alfredo Nicosia likes to say, the Basel-based biotech is a relative fledgling at 2-years of age. But the core research team there has been working together for quite a few years.
Nicosia and co-founder Riccardo Cortese — the original NousCom CEO who died earlier this year — had managed Okairos until GlaxoSmithKline came along to bag the company and its tech for spurring an immune assault on infectious diseases for $325 million in 2013. And now Nicosia and the team are off building a pair of new platforms, keying off of their knowledge of the immune system in the sizzling hot immuno-oncology arena, with a fresh $49 million round to push the lead program into the clinic next year.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.